Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Parkinson’s disease

Dec 30, 2022

Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management

Jul 19, 2022

Byondis’s HER2-targeting ADC trastuzumab duocarmazine; AbbVie Migraine Drug Atogepant; Grünenthal Acquires Bayer’s Testosterone Drug Rights; Vertex Acquires ViaCyte; Merck & Orion Announces Collaboration; Verve Starts Trials of Cholesterol Drug; Kyowa Kirin Drops Nourianz follow-up KW-6356; FDA Orphan Drug and Fast Track Designations to CV-01

May 24, 2022

PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboration with Atara; FDA Accepts Biohaven’s Zavegepant; AbbVie Files FDA Approval for ABBV-951; Innoviva to Acquire Entasis; FDA Orphan Drug Designation to XMT-2056; FDA Approves Azacitidine for Juvenile Myelomonocytic Leukemia

May 12, 2022

Abbott’s Alinity m STI Assay; Phillips’ MR 7700 System; HOYA’s MiYOSMART Spectacle Lens; Magneto’s Pulmonary Embolism Treatment; Owen Mumford and Stevanto Group’s Collaboration Deal; Elekta’s Radiosurgery System-Elekta Esprit

Feb 25, 2022

Most Promising Therapies in the Parkinson’s Disease Treatment Market

Dec 31, 2021

Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market

Mar 26, 2021

How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain?

Feb 26, 2021

Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore!

Jan 11, 2021

Parkinson’s Disease: How close are we to a cure?

Dec 04, 2020

Advancements in Neuromodulation

Newsletter/Whitepaper